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ABSTRACT
Background: Hepatitis C is a global health problem and represents a major cause of liver 
disease and socioeconomic burden. Effective antiviral therapy may prevent these complica-
tions, but the current treatment for patients with chronic hepatitis C virus (HCV) infection 
does not produce sustained virologic response. Therefore, identification of the determinants 
of response to treatment is a high priority. A number of host and viral factors have been as-
sociated with treatment outcomes.
Objectives: To assess the associations of single nucleotide polymorphisms (SNP) of the IL28B 
and sustained virologic response (SVR) of patients with chronic hepatitis C to PEG-interferon/
ribavirin therapy.
Materials and Methods: We searched PubMed, Medline and Cochrane Library, and found 7 eli-
gible papers involved in this study. Then we performed a meta-analysis comparing the SVR 
rate at SNP of the IL28B in individuals with PEG-interferon/ribavirin therapy. Meanwhile, the 
SVR rate between different races and HCV genotypes was studied.
Results: The sustained virologic response rate was higher in patients with the rs12979860 
CC and rs8099917 TT alleles in the IL28B SNP, comparing with the rs12979860 CT, or TT and 
rs8099917 TG or GG. Furthermore, a higher SVR was observed in the Caucasians than in Afro-
Americans (OR = 3.85, 95% CI: 3.06–4.83); the percentage of rs12979860 TT genotype was lower 
in Caucasians (OR = 0.25, 95% CI: 0.20–0.31) and the percentage of rs12979860 CC genotype 
was higher in Caucasians than that of Afro-Americans (OR = 3.45, 95% CI = 2.68-4.44). Between 
different HCV genotypes, the SVR was much lower in those with HCV genotype 1 than those 
with genotype 2/3 (OR = 0.16, 95% CI: 0.11–0.24).
Conclusions: IL28B is significantly associated with response to PEG-interferon/ribavirin thera-
py of patients with chronic HCV infection. Both the rs12979860 and rs8099917 alleles could be 
used as independent predictors of the treatment response. The rs12979860 allele in particu-
lar, is more important from our study. The polymorphism even explains part the difference 
in response rate between different ethnic groups and HCV genotypes.
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Background
Hepatitis C is a global health problem and represents a ma-
jor cause of liver disease and socioeconomic burden. There 
were 120–180 million hepatitis C virus (HCV) carriers world-
wide, with worldwide prevalence estimated at 3% (1-3), and 
a new 3–4 million cases appearing each year (2). Only a mi-
nority of these infected patients spontaneously clear HCV. 
  Implication for health policy/practice/research/medical education: 
Nowadays, the role of genetic factors and background in response to treatment regimens like PEG-interferon/ribavirin of patients with hepa-
titis C is highly considered. Gastroenterologists and/or geneticians should be aware of the role of IL28B in prediction of response to therapy 
in HCV patients.
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Failed to clear, 70%–80% of patients become chronic carriers 
(4), who may progress to liver cirrhosis and hepatocellular 
carcinoma (HCC) leading to the need of liver transplantation 
(5-7). Effective antiviral therapy may prevent these complica-
tions, but the current treatment for patients with chronic 
HCV infection, a combination of pegylated interferon-α 2a 
or 2b (PEG-IFN-α) given by injection with oral ribavirin (RBV), 
does not produce sustained virologic response (SVR) in all 
patients treated. This treatment is not only long and costly, 
but also associated with significant side effects (e.g., a flu-like 
syndrome, hematologic abnormalities and adverse neurop-
sychiatric events) (8), resulting in reduced compliance and 
fewer patients completing the treatment. For these reasons, 
identification of the determinants of response to treatment 
is a high priority. A number of host and viral factors have 
been associated with treatment outcomes (9-12).
The viral factors, including HCV genotype, baseline viral 
load, viral kinetics during treatment, and amino acid pat-
tern in the interferon sensitivity-determining region, have 
been fully studied (13-15). HCV genotype, in particular, is used 
in making treatment decisions: patients with HCV genotype 
2/3 have a relatively high rate of SVR (70%–80%) with 24 weeks 
of treatment, whereas those infected with HCV genotype 1 
have a much lower rate of SVR (40%–52%) despite 48 weeks 
of treatment (16-19). The host factors include age, sex, body 
mass index (BMI), insulin resistance, hepatic steatosis, he-
patic fibrosis and ethnicity (9, 12, 18, 20-22). Recently, several 
highly  correlated  single  nucleotide  polymorphisms  (SNP) 
on a linkage disequilibrium block in the vicinity of 3 IFN-λ 
genes on chromosome 19, encoding INF-λ1 (IL29), λ2 (IL28A), 
and λ3 (IL28B), have been implicated in response to PEG-IFN/
RBV among patients infected with HCV from four studies 
(23-26), which also seems to explain part of the difference 
in response between different races (23) and HCV genotypes 
(26). Even with a lot of researches in this field, there is a con-
troversy about it.
Objectives
To  clarify  the  role  of  rs12979860  and  rs8099917  alleles, 
which were researched the most of IL28B, in treatment re-
sponse of patients with chronic hepatitis C (CHC) to PEG-IFN/
RBV, we carried out a meta-analysis of the available cohort 
studies of the association between the SNP of IL28B and the 
SVR of patients with CHC treated with PEG-IFN/RBV.
Figure 1. Flow diagram of literature search.Hepat Mon. 2011;11(3):163-172
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Materials and Methods
Selection criteria
Analytic epidemiological studies (cross-sectional, indepen-
dent replication cohort, or genome-wide association study) 
that examined the SNP of IL28B in response to PEG-IFN/RBV 
among patients infected with HCV were reviewed. Attempts 
were made to contact the authors where data was missing, by 
e-mail. The following studies were included in the review:
1. Articles in English only were included in the review.
2. Observational epidemiological studies were included.
3. Articles were limited to humans only.
4. Conference reports.
Exclusion criteria
1. Case reports.
2. Case series.
3. Studies not limited to humans.
4. Studies not in English.
5. Studies that did not provide enough information to cal-
culate the treatment effects.
Literature search
We identified the studies by searching PubMed, Medline 
and  Cochrane  Library  with  the  following  search  terms: 
(“IL”[MeSH]  OR  “interleukin”[MeSH])  AND  (“INF”[MeSH] 
OR  “interferon”[MeSH])  AND  (“hepatitis  B”[MeSH]  OR 
“HBV”[MeSH] OR “CHB”[MeSH] OR “hepatitis C”[MeSH] OR 
“HCV”[MeSH]) AND (“SNP” [MeSH] OR “polymorphism”[MeSH] 
OR  “mutation”[MeSH])  AND  “humans”[MeSH].  The  initial 
search done on May 20, 2010, retrieved 78 articles. The ab-
stracts of these 78 papers were read by two reviewers inde-
pendently. After screening with both the selection criteria 
and exclusion criteria, only 27 studies were found eligible 
for further evaluation. Then 21 papers were excluded for not 
meeting the inclusion criteria with a deeper review. Three 
additional studies from a second time search, done on June 
24, 2010, were also included. In the nine left papers, one was 
excluded because of insufficient data (27), another article 
was in French, and its full-text was not available (28). And, 
two conference reports from the 2010 ASDL found to be eli-
gible based on their abstracts, but the detailed data were not 
available after contacting their authors. Thus, in the final 
analysis, seven articles (23-26, 29-31) were included (Figure 1), 
with a total number of 4791 patients studied.
Data extraction
A full detailed description of each study cohort is presented 
in Table 1. Study subjects from Switzerland were came from 
the Swiss Hepatitis C Cohort Study and the Swiss HIV Cohort 
Study,  two  multicenter  studies  performed  at  eight  major 
Swiss hospitals and their local affiliated centers (32, 33), and 
from the Medical Clinic for Hepatology and Gastroenterol-
ogy, Medical University Charité Campus, Virchow-Klinikum 
Berlin, in Berlin, Germany. A genome-wide association study 
of  sustained  virological  response  (SVR)  to  PEG-IFN-α/RBV 
combination therapy with genotype 1 chronic hepatitis C 
was performed in three studies from USA (9) and Australia, 
disparate an additional replication cohort of white people 
from  the  Australian,  and  a  further  prospective  treatment 
study from one of the USA (12). Another study from USA was 
based on a cross-sectional study. And, the subjects from Japan 
were patients with CHC at the Graduate School of Medicine, 
Kanazawa University Hospital and its related hospitals.
Definition of main concepts
SVR was defined as “having undetectable HCV-RNA levels 24 
weeks after cessation of treatment.” Non-responders were 
patients whose HCV-RNA levels remained detectable at the 
end of treatment. Those who had undetectable levels of HCV-
RNA at the end of treatment, but detectable HCV-RNA levels 
at 24 weeks after cessation of treatment were called “relaps-
ers.”  Both  the  non-responders  and  relapsers  were  catego-
rized as non-viral response (NVR). Rapid viral response (RVR) 
was with an undetectable HCV-RNA levels at four weeks and 
early viral response (EVR) was at 12 weeks.
Statistical analysis
Study
Sample 
size
Race Genotype Drug
Therapy 
time
Follow-up 
time
Efficacy meas-
ures
Ge D, et al. 
(2009)
1137 946 (Caucasians) 
191 (Afro-Americans) 
1137 (1) PEG-IFN-α-2a 
or -2b/RBV
48 wk 24w SVR, non-SVR
Suppiah V, et al .
 (2009)
848 848 (Caucasians)  848 (1) PEG-INF-α/RBV 48 wk 24w SVR, NR
Tanaka Y, et al. 
(2009)
314 314 (Asians) 314 (1) PEG-INF-α/RBV 48 wk 24w SVR, VR, NR
Honda M, et al. 
(2009)
168 168 (Asians) 168 (1) PEG-INF-α-2b/
RVB
48 wk 24w SVR, TR, NR, EVR
McCarthy JJ, et al. 
(2009)
231 178 (Caucasians) 
53 (Afro-Americans)
186 (1)
45 (2/3)
NA NA 24w SVR, NR, Relapsers
Rauch A, et al. 
(2009)
465 465 (Caucasians) 188 (1)
222 (2/3)
34 (4)
21 (others)
PEG-INF-α/RBV 48 wk 24w SVR, NR
Thompson AJ, et al. 
(2009)
1628 1287 (Caucasians)
300 (Afro-Americans)
41 (Others)
1628 (1) PEG-INF/RBV 48 wk 24w SVR, EVR, RVR
Table 1. Descriptive baseline characteristics of the subjects included in this studyHepat Mon. 2011;11(3):163-172
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Figure 2. Analysis of the association between SNP of IL28B (rs12979860) and SVR of patients with chronic hepatitis C treated with PEG-INF/RBV. A: Compared the 
SVR between CC and CT genotypes; B: Compared the SVR between CC and TT genotypes; C: Compared the SVR between CT and TT genotypes
The main outcome of interest was odds ratios (OR), which 
estimated  the  association  between  SNP  of  IL28B  and  the 
treatment  response.  Crude  association  estimates  and  95% 
confidence intervals (95% CI) from each study were calculat-
ed, and displayed by forest plots. In the forest plot, the rela-
tive weight of each study’s contribution to the analysis was 
represented by the area of box whose center represents the 
estimated measure of association. Both the fixed effect mod-
el and random effects model were used in this meta-analy-
sis. The random effects model provides a way to address the 
heterogeneous studies which varied in their design, char-
acteristics, and sampled populations and other factors con-
tributing to variation in the data. The estimated confidence 
interval will be wider than that from a fixed effect model if 
there is heterogeneity among the studies and, thus, protects 
against falsely assuming a significant difference when there 
is none. Random effects model is used when the Q statistic 
obtained is significant which indicates that there is variabil-
ity among the effect sizes which may be attributed to factors 
or sources which may not be identifiable or measurable. But 
the fixed effect model is chosen if the Q statistic obtained is 
not significant. All analyses were done with Review Manager 
ver 4.2.2.
Results
Characteristics of studies
A total of 4791 patients were assessed for this study. A de-
tailed  description  of  each  study  cohort  was  presented  in 
Table 1. Three of the world main ethnicities were all included. 
The Caucasians, Hispanics and the Australian population of 
northern European ancestry, which was mentioned only in 
one study, were all typed into the Caucasian group. Others Hepat Mon. 2011;11(3):163-172
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were named as Afro-Americans and Asians in our study. All 
the studies included were carried out in populations with 
mean age ranging from 43.4 to 57.4 years. There was a pre-
ponderance of males in all studies but one ranging from 
54.5% to 64.9% of the subjects. Other detailed information in-
cluded the HCV genotype, baseline HCVAb level, treatment 
history and METAVIR fibrosis stage.
The association between SNP of IL28B (rs12979860) and 
SVR of CHC patients with PEG-INF/RBV therapy
In  the  seven  included  papers,  only  four  studied  the 
rs12979860  alleles.  We  first  included  this  four  studies  to 
evaluate the association between SNP of IL28B (rs12979860) 
and SVR of CHC patients with PEG-INF/RBV therapy. Compar-
ing with the patients of rs12979860 CT genotype, greater SVR 
was observed in the patients of rs12979860 CC in the four 
analyzed trials, (704/998 [70.5%] vs 477/1491 [32.0%], OR = 5.22, 
95% CI: 4.37–6.23, p < 0.001) (Figure 2A). When comparing the 
CC and TT genotype, greater SVR was observed in the patients 
of rs12979860 CC (704/998 [70.5%] vs 116/498 [23.3%], OR = 7.97, 
95% CI: 6.20–10.25, p < 0.001) (Figure 2B). When it came to the 
CT and TT genotype, greater SVR was observed in the patients 
of rs12979860 CT (447/1491 [32.0%] vs 116/498 [23.3%], OR = 1.56, 
95% CI: 1.23–1.97, p < 0.001) (Figure 2C).
The association between SNP of IL28B (rs8099917) and SVR 
of CHC patients with PEG-INF/RBV therapy
There  were  four  papers  studied  the  rs8099917  alleles  in 
the seven included articles. The evaluation of the associa-
tion between SNP of IL28B (rs8099917) and SVR of CHC pa-
tients with PEG-INF/RBV therapy were done based on these 
four studies. Greater SVR was observed in the patients of 
rs8099917 TT, comparing with the patients of rs8099917 TG 
genotype (585/928 [63.0%] vs 234/654 [35.8%], OR = 4.23, 95% 
Figure 3. Analysis of the association between SNP of IL28B (rs8099917) and SVR of patients with chronic hepatitis C treated with PEG-INF/RBV therapy. A: Com-
pared the SVR between TT and TG genotypes; B: Compared the SVR between TT and GG genotypes; C: Compared the SVR between TG and GG genotypesHepat Mon. 2011;11(3):163-172
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Figure 4. Analysis of the association between the rate of SVR and ethnicity
CI: 2.01–8.88, p < 0.001) (Figure 3A). When focusing the TT 
and GG genotype, greater SVR was observed in the patients 
of rs8099917 TT (585/928 [63.0%] vs 25/77 [32.5%], OR = 3.40, 
95% CI: 2.07–5.59, p < 0.001) (Figure 3B). But between the TG 
and GG genotype, the difference was not significant (234/654 
[35.8%] vs 25/77 [32.5%], OR = 1.28, 95% CI: 0.77–2.12, p = 0.35) 
(Figure 3C).
The  association  between  the  SNP  of  IL28B  (rs12979860) 
and SVR of chronic hepatitis C patients with PEG-INF/RBV 
therapy by race
Only three of the seven included papers studied both the 
Caucasians and Afro-Americans, despite three of the world 
main ethnicities were all included. And, they were all dis-
cussed the rs12979860 alleles only. From these three papers, 
a higher SVR was observed in the Caucasians than Afro-Amer-
icans (1175/2411 [48.7%] vs 107/544 [20.0%], OR = 3.85, 95% CI: 
3.06–4.83, p < 0.001) (Figure 4). Then, we searched the associa-
tion between the percentage of each genotype of rs12979860 
and  people  ethnicities.  The  percentage  of  TT  genotype 
was  lower  in  the  Caucasians  than  that  of  Afro-Americans 
(300/2411 [12.4%] vs 197/544 [36.2%], OR = 0.25, 95% CI: 0.20–
0.31, p < 0.001) (Figure 5A). The percentage of CC genotype 
was higher in the Caucasians than that of Afro-Americans 
(900/2411 [37.3%] vs 80/544 [14.7%], OR = 3.45, 95% CI: 2.68–4.44, 
p < 0.001) (Figure 5B). When it came to CT genotype, however, 
the percentage was not significant between the Caucasians 
and Afro-Americans (1211/2411 [50.2%] vs 267/544 [49.1%], OR = 
1.05, 95% CI: 0.87–1.27, p < 0.001) (Figure 5C).
The association between the SNP of IL28B (rs12979860 and 
rs899917) and SVR of chronic hepatitis C patients with PEG-
INF/RBV therapy by HCV genotype
In the seven included papers, only two investigated differ-
ent  HCV  genotypes.  We  grouped  them  into  the  genotype 
1  and  genotype  2/3  group  because  the  genotypes  2  and  3 
cannot be separated clearly according to one of this initial 
study. About the IL28B, one was focused on the rs12979860 al-
lele, while another was focused on rs8099917. First, we did a 
meta-analysis of the association between the rate of SVR and 
HCV genotype. A lower SVR was observed in the HCV geno-
type 1 group, comparing with genotype 2/3 (129/347 [37.2%] vs 
216/267 [80.9%], OR = 0.16, 95% CI: 0.11–0.24, p < 0.001) (Figure 
6). Then the two different loci of IL28B were analyzed sepa-
rately. The percentage of rs12979860 CC was much higher 
in HCV genotype 2/3 (50.0%) than that of genotype 1 (33.5%, 
p < 0.001). But the percentage of rs8099917 TT among HCV 
genotype 2/3 (63.9%) and genotype 1 (55.6%, p = 0.07) was not 
much different (Figure 7).
Discussion
Multiple viral and host factors may be related to the treat-
ment response to PEG-IFN/RBV combination therapy for the 
CHC patients. For the host factors, the hepatic INF-stimulat-
ed genes (ISGs), such as Myxovirus resistance 1 (Mx1), 2'-5'-
oligoadenylate synthetase 3 (OAS3), INF-induced protein 44 
(IFI44), INF-induced protein 44-like (IFI44L), 2'-5'-oligoade-
nylate synthetase 2 (OAS2), ubiquitin specific peptidase 18 
(USP18), radical S-adenosyl methionine domain containing 2 
(RSAD2), INF-induced with tetratricopeptide repeats 1 (IFIT1), 
INF-induced with helicase C domain 1 (IFIH1), XIAP associated 
factor-1 (XAF1), cytidine monophosphate kinase 2 (CMPK2), 
epithelial stromal interaction 1 (breast) (EPSTI1), hect domain 
and  RLD  6  (HERC6),  poly  (ADP-ribose)  polymerase  family, 
member 9 (PARP9), and phospholipid scramblase 1 (PLSCR1) 
were all reported earlier. But the interesting phenomenon 
was  that  the  IL28B  genotype  was  demonstrated  to  be  a 
strongly independent predictor of the treatment response 
for  the  CHC  patients  in  a  multivariate  logistic  regression 
analysis among many other host and viral factors, nearly in 
all the studies included. The role of IL28B was reported a lot 
recently, which was also thought to be associated with spon-
taneous HCV clearance (34), and a significant independent 
predictor of response to PEG-IFN/RBV in patients with chron-
ic HCV infection (26). From Dongliang Ge, et al, the genetic 
polymorphism near the IL28B gene (rs12979860) was associ-
ated with an approximately two-fold change in response to 
treatment, both among patients of European ancestry and 
Afro-Americans. And, the greater frequency of the genotype 
leading to better response (rs12979860 CC alleles) in Euro-
pean than African populations, also explains approximately 
half of the difference in response rates between Afro-Amer-
icans and patients of European ancestry (23). Other stud-
ies emphasize that the major effect of this polymorphism 
(rs12979860) was to increase the rate of early viral decline, 
leading to higher SVR rates (30). Moreover, Masao H, et al. 
(29), demonstrated that expression of INF-stimulated genes 
(ISGs), a new reported determinant viral factor, was related to 
genetic variation in IL28B. To the contrary, two SNPs near the 
gene IL28B on chromosome 19 (rs12980275 and rs8099917) Hepat Mon. 2011;11(3):163-172
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were found to be strongly associated with NVR.
The protein product of IL-28B is IFN-λ-3, one of the three 
members of the recently described type III IFN family (IFN-λ-
1/2/3 = IL-29, IL-28A, and IL-28B) (35, 36), which have been stud-
ied previously in the context of HBV and HCV infection and 
shown to suppress both HBV and HCV replication (37-39). In 
co-stimulation experiments, IFN-λ and IFN-α have an additive 
antiviral effect. But the mechanisms through which IL-28B 
variant genotypes influence antiviral response to PEG-IFN-α/
RBV remain unclear. Some researches believe in a major role 
of the innate immunity in the control of HCV. IFN-λ interacts 
with a transmembrane receptor to induce potent antiviral 
responses (35, 36). This antiviral activity is mediated through 
the activation of the J AK-STAT (IFN-α, IFN-λ, and IFN-λ) and 
MAPK (IFN-α and IFN-λ) pathways. In vitro and in vivo mod-
els have shown the importance of IFN-λ in the immune re-
sponse to several viral pathogens, including herpes simplex 
virus (40, 41), cytomegalovirus (42), HIV (43), hepatitis B and 
C virus (44). IFN-λ1 and IFN-λ2 block HCV replication in hu-
man hepatocytic cell lines (37-39). Other studied explained 
the antiviral activity by mediating the ligand for TLR3 and 
TRL9, an antiviral protection (39, 44).
The mechanism of rs12979860 allele, which located 3 kb up-
stream of the IL28 gene, and rs8099917, locating 8.9 kb from 
the end of transcription of IL28B and 16 kb from the end of 
transcription  of  IL28A,  related  to  PEG-IFN-α/RBV  response 
is not yet known. It is likely that the activity or levels of the 
nearby  IFN-λ  genes  is  influenced,  because  responders  to 
treatment are characterized as having a lower baseline im-
mune response to HCV (45, 46). This could also explain the 
paradoxical association of the response genotype with high-
er viral load in the study by Ge, et al (22). In this meta-analy-
sis, either the rs12979860 CC genotype or rs8099917 TT geno-
type received a much better response of therapy, regardless 
Figure 5. Analysis of the association between the percentage of each genotype of rs12979860 and ethnicity. A: Compared the percentage of TT genotype; B: Com-
pared the percentage of CC genotype; C: Compared the percentage of CT genotypeHepat Mon. 2011;11(3):163-172
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Figure 6. Analysis of the association between the rate of SVR and HCV genotype
Figure 7. Association between IL28B and HCV genotype. A: The rs12979860 CC percentage in different HCV genotypes (by the study of McCarthy JJ, et al); B: The 
rs8099917 TT percentage in different HCV genotypes (by the study of Rauch A, et al)
of comparing with the rs12979860 CT genotype/rs8099917 
TG genotype or the rs12979860 TT genotype/rs8099917 GG 
genotype. For this reason, the results supported that the C 
base at 12979860 and the T base at rs8099917 were the advan-
taged bases leading to better response to the combination 
therapy of PEG-INF/RBV. And, the difference was higher in 
the  major  homozygote  (rs12979860  CC/rs8099917  TT)  and 
heterozygote, compared with the heterozygote and the mi-
nor homozygote (rs12979860 TT/rs8099917 GG), which indi-
cated a more important role of the risk base (rs12979860 T/
rs8099917 G) in the treatment effect than that of protective 
base (rs12979860 C/rs8099917 T). But the rs12979860 seemed 
to be more related to a better response.
The  patients  of  European  ancestry  had  a  significantly 
higher probability of being cured than patients of African 
ancestry. The percentage of rs12979860 CC in the Caucasians 
was much higher than that of Afro-Americans, fitting the 
much lower percentage of rs12979860 TT in the Caucasians 
than  that  of  Afro-Americans.  This  proved  that  the  C  base 
at 12979860 was the advantaged base leading to better re-
sponse  to  the  combination  therapy  of  PEG-INF/RBV  again 
and at the same time the T base at 12979860 was a risk fac-
tor for treatment from another aspect. It also explains part 
of the reason that the difference of therapy response in dif-
ferent ethnicities may be due to the different occurrence of 
rs12979860 genotypes. Similarly, the HCV genotypes 2/3 had 
a much greater SVR than that of genotype 1. The percentage 
of rs12979860 CC in the HCV genotypes 2/3 group was higher 
than that of genotype 1, but the difference of rs8099917 TT 
percentage in the HCV genotypes 2/3 group and genotype 1 
was not much significant. It seemed to explain part of the 
reason that the difference of therapy response in different 
HCV genotypes may be related to the SNP of IL28B. But the 
current data was not suitable for a meta-analysis.
Furthermore, the role of baseline HCV-RNA, liver fibrosis 
stage, and drug type in the SVR of PEG-INF/RBV therapy was 
not clear according to the present included data. We con-
cluded that the polymorphism of IL28B is significantly as-
sociated with response to PEG-IFN/RBV therapy for patients 
with chronic HCV infection. Rs12979860, in particular, could 
be used as an independent predictor of the treatment re-
sponse. And, the polymorphism explains part the difference 
in  response  between  different  ethnicities  and  HCV  geno-
types. Further studies are needed to explore the mechanism 
of the reported genetic association at IL28B, and the associa-
tion of this polymorphism and other treatment response 
impacting factors such as the baseline HCV-RNA, gender and 
age. 
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